CN108888608A - A kind of application of the preparation method and its fat reducing protect liver of the nano-carrier carrying resveratrol - Google Patents
A kind of application of the preparation method and its fat reducing protect liver of the nano-carrier carrying resveratrol Download PDFInfo
- Publication number
- CN108888608A CN108888608A CN201810741557.9A CN201810741557A CN108888608A CN 108888608 A CN108888608 A CN 108888608A CN 201810741557 A CN201810741557 A CN 201810741557A CN 108888608 A CN108888608 A CN 108888608A
- Authority
- CN
- China
- Prior art keywords
- nano
- resveratrol
- carrier
- carrying
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Abstract
The invention discloses the applications of the preparation method and its fat reducing protect liver of a kind of nano-carrier for carrying resveratrol.Resveratrol is added to the organic macromolecule polymer such as PLGA for being dissolved in organic solvent, and then carries out ultrasonic emulsification processing, after then removing organic solvent by volatilization, a kind of nano-medicament carrier particle for being loaded with drug in regular spherical can be obtained.The nano-carrier have the characteristics that stability height, small toxicity, high encapsulation rate, slow releasing pharmaceutical, suitable for oral, in addition, being administered using the nano-carrier, the bioavailability and solubility of drug can be improved, required dosage thus can be effectively reduced, further decreases side effect.And organic macromolecule polymer P LGA, lipid components can be effectively absorbed, can be effectively reduced free fatty acid and glycerol etc. in blood lipid and blood.
Description
Technical field
The present invention relates to pharmaceutical technology field more particularly to it is a kind of carry resveratrol nano-carrier preparation method and its
The application of fat reducing protect liver.
Background technique
Obesity is defined as a kind of internal accumulation hyperliposis for jeopardizing human health or abnormal distribution by the World Health Organization
Disease.Obesity is a kind of chronic persistent state, by body fat it is excessive with the characteristics of.Obesity this with it is thin for beauty when
In generation, it is aesthetic not meet mainstream not only, also will affect health, brings a series of complication, such as diabetes B, biliary tract
Disease, conisting of dyslipidemia, insulin resistance, sleep apnea, expiratory dyspnea, undying anxiety, coronary heart disease, hypertension,
Osteoarthritis, various cancers, reproductive hormone exception, Stein-Leventhal syndrome etc..
Non-alcoholic fatty liver disease (nonalcoholic fatty liver disease, NAFLD) refer to except alcohol and
Caused by other clear factors, clinical pathology syndrome characterized by inflammation in hepatic parenchymal cells steatosis and lobuli hepatis is
Heredity-environment-metabolic stress is diseases related, including simple fatty liver (nonalcoholicsimplefattyliver) and
The nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) and cirrhosis developed by it.Non-alcoholic rouge
Fat hepatopathy early stage stable disease, more early treatment are better.Nonalcoholic fatty liver disease is the inflection point of state of an illness conversion and the weight of prevention and treatment
Point is easy to develop into cirrhosis.
Fat essence is that the intake of body energy is greater than the consumption of energy, eventually leads to the accumulation of fat.Non- alcohol
Property fatty liver pathogenesis it is complicated, generally speaking, be also due to body insulin resistance, oxidative stress and lipid peroxidation
The reason of, cause the impaired then fat deposition of liver cell to cause steatosis, and then continue the process deteriorated.So
Illness early stage reduces the aggregation of fat in time, promotes the decomposition of fat, is of great significance for weight-reducing and protect liver.
Resveratrol (Resveratrol) is a kind of non-flavonoids polyphenolic substance, at present in polygonum cuspidate, grape, peanut
Deng the presence for finding resveratrol at least 72 kinds of plants, and research shows that resveratrol has a variety of pharmacological activity, have
The pharmacological actions such as anticancer, anti-inflammatory, anti-oxidant, protection angiocarpy, are with a wide range of applications, the huge market demand.But it is fresh
Someone reported the effect of fat reducing protect liver of resveratrol, and as a kind of natural component, to human body Small side effects.White black false hellebore
Alcohol is insoluble in water, is soluble in organic solvent（Such as acetone, ether, methanol, ethyl acetate, chloroform）, to photo-labile.It this
A little performance degree of making it dissolve are low, bioavilability is low, pharmaceutical activity is unstable, the application of the resveratrol of limitation.Therefore it is badly in need of
A kind of method improves these disadvantages, expands the application of resveratrol.
Nano-medicament carrier can play pharmacological action to the maximum extent, while overcome drug itself in drug delivery
Limitation and disadvantage.Nanotechnology is greatly improved the form of therapy and diagnosis efficiency of various diseases, in drug manufacture view
Also its unique advantage is shown.Nano-carrier is commonly used for the diagnosing and treating of cancer, fresh less in terms of fat reducing.The present invention
Using nanotechnology, resveratrol is wrapped among nano-carrier, so as to improve its solubility, improves bioavailability and medicine
The stability of object itself plays the role of fat reducing protect liver to preferably play drug effect.
Summary of the invention
An object of the present invention is to provide a kind of slow release nanometer carrier for carrying resveratrol.The second purpose is to provide this
The production method of nano-carrier.The third purpose is to provide new application-fat reducing shield of this slow release nanometer carrier for carrying resveratrol
Liver.
The present invention provides a kind of nano-carriers for preparing load resveratrol.Resveratrol addition is dissolved in organic molten
The organic macromolecule polymer such as PLGA of agent, and then ultrasonic emulsification processing is carried out, after then removing organic solvent by volatilization,
A kind of nano-medicament carrier particle that drug is loaded in regular spherical can be obtained.The nano-carrier has stability height, toxicity
Small, high encapsulation rate, slow releasing pharmaceutical, the feature suitable for taking orally.In addition, being administered using the nano-carrier, drug can be improved
Bioavailability and solubility, it is thus possible to effectively reduce required dosage, further decrease side effect.
The present invention provides the new application-fat reducing protect livers for the slow release nanometer carrier for carrying resveratrol.PLGA is as organic big
Molecule is absorbed, this can further promote fat since it is with lipophilicity in the glycerol that the discovery of application process is decomposed
The case where decomposing, reducing glycerol and free fatty acid, avoid the occurrence of hyperlipidemia.And resveratrol is wrapped up with nano-carrier, it mentions
The high solubility of itself, bioavailability, stability are there are also half-life period in vivo, slow release that can be permanently effective
Drug makes it maintain active drug concentration, thus the effect of playing fat reducing protect liver.
A kind of preparation method for the nano-carrier carrying resveratrol, includes the following steps：
（1）By drug and the organic macromolecule mixed with polymers for being dissolved in organic solvent, ultrasound is to obtain the i.e. oily phase of mixed solution；
The drug is resveratrol.
（2）By the mixed solution with containing the aqueous solution of emulsifier, i.e. water phase carries out emulsification ultrasonic treatment, to obtain
Oil-in-water emulsion；
（3）The oil-in-water emulsion is successively stirred（To remove organic solvent）, centrifugation and carrying out washing treatment, obtain and carry white Chenopodiaceae
The nano-carrier of reed alcohol.
In the above method, the organic macromolecule polymer is selected from one of PLGA, PEG, PLGA-PEG.
In the above method, the organic solvent is selected from one or more of acetone, methylene chloride, ethyl acetate.
In the above method, step（1）And step（2）In, the power of the ultrasound in 100 ~ 500w, ultrasonic time is 1 ~
10min。
In the above method, the emulsifier is selected from one of BSA, PVA, CTAB, Tween 80.
In the above method, step（3）In, the mixing time be 3 ~ for 24 hours, centrifugal speed be 8000 ~ 14000rpm, washing
Number is 2 ~ 5 times.
It is a kind of carry resveratrol nano-carrier be applied to fat reducing protect liver, it is described carry resveratrol nano-carrier have subtracts
The new application of rouge, protect liver.
In above-mentioned application, the nano-carrier for carrying resveratrol is applied in weight-reducing and liver-protecting product, plays reduction rouge
The effect of tired, the long-pending promotion lipolysis of fat.
It is a kind of carry resveratrol nano-carrier have stability height, small toxicity, high encapsulation rate, slow releasing pharmaceutical, be suitable for
Oral feature.
Compared with prior art, advantage of the invention is that：
1. resveratrol is natural drug, so for the toxic side effect very little of human body, and it is living with very strong biology
Property -- there are the physiological actions such as fat reducing, anticancer, anti-inflammatory, anti-oxidant, protection angiocarpy, be with a wide range of applications, market needs
The amount of asking is big.
2. due to the characteristic of resveratrol itself -- it is insoluble in water, is soluble in organic solvent（As acetone, ether, methanol,
Ethyl acetate, chloroform etc.）, to photo-labile.Its these performance degree of making it dissolve are low, bioavilability is low, pharmaceutical activity not
Stablize, the application of the resveratrol of limitation.The present invention provides a kind of nano-carriers for preparing load resveratrol, will by carrier
It, which is encapsulated, can greatly improve the water solubility of resveratrol, in photostability and application process its bioavilability and
Pharmaceutical activity.
3. the nano-carrier provided by the invention has manufacturing process simple, stability height, high encapsulation rate, delays small toxicity
Release the drug object, the feature suitable for taking orally.In addition, be administered using the nano-carrier, can be improved drug bioavailability and
Solubility, it is thus possible to effectively reduce required dosage, further decrease side effect.
4. the present invention provides the new application-fat reducing protect livers for the slow release nanometer carrier for carrying resveratrol.Pass through research, hair
Now the nano-carrier can reduce the fat content in fat cell, also can reduce fatty in fatty liver cell model contain
Amount, it is possible in terms of the carrier can be applied to fat reducing protect liver.
Detailed description of the invention
Fig. 1 is resveratrol（Res）, PLGA and the nano-carrier that resveratrol is contained with PLGA（Res-PLGA-NPS）'s
Infrared spectrogram；
Fig. 2 is the grain size distribution of Res-PLGA-NPS；
Fig. 3 is the Zeta potential distribution map of Res-PLGA-NPS；
Fig. 4 is the scanning electron microscope (SEM) photograph of Res-PLGA-NPS；
Fig. 5 is the In-vitro release curves of Res in Res-PLGA-NPS；
Fig. 6 is oil red O stain figure of the various concentration Res-PLGA-NPS to the HepG2 cell that induction is fatty liver cell；
Fig. 7 is oil red O stain figure of the Res-PLGA-NPS to the 3T3-L1 fat cell of induced maturation.
Specific embodiment
Embodiment 1
One, the preparation of the nanoparticle of resveratrol is carried：
10mgPLGA is dissolved in 1ml methylene chloride and acetone（Volume ratio methylene chloride：Acetone=3：2）, form uniform PLGA solution
（10mg/ml）.The resveratrol that 8mg is added into PLGA solution is dissolved in ethyl alcohol, and ultrasound 1min generates s/o primary at 100w
Then primary emulsion is slowly injected into the BSA solution of 5ml 1% by lotion, and ultrasound 1min forms final s/ at 100w
O/w lotion.In order to disperse final s/o/w lotion, 10ml deionized water is added, magnetic agitation 4h is remaining organic molten to remove
Agent.Nanoparticle is collected, 30min is centrifuged at 14000rmp and removes supernatant, to obtain NPS.Then plus deionization is washed three times,
20min is centrifuged under 10000rpm.It is finally freeze-dried, puts 4 DEG C with spare.
Two, test method
1, the characterization of nanoparticle
1.1 infrared spectroscopy
Pass through the relevant functional group of structure and composition of infrared absorption spectrum authenticating compound using FTIR method.With ATR attachment
Res, the infrared spectroscopy of PLGA, Res-PLGA-NPS are detected in the case where wavelength is 4000-400cm-1.
1.2 partial sizes and Zeta potential
Use Zetasizer Nano-ZS90（Malvern Instrument, Worcestershire, UK）It is dissipated by dynamic optical
It penetrates（DLS）Measure the partial size and Zeta potential of NUC-PLGA-NPS.
1.3 scanning electron microscope
The form and size of dry Res-PLGA-NPS are measured using Scanning electron microscopy (SEM).
The hanging drop of one drop Res-PLGA-NPS is placed on the clean silicon wafer that ethanol postincubation is crossed and in room temperature（RT）Lower drying.
2, release in vitro
The Res-PLGA-NPS of 10mg is dissolved in 5ml ionized water, 4ml is then drawn in bag filter, is placed on
The PBS that PH is 7.4.It is continuously shaken in 37 DEG C, the shaking table of 100rpm and carries out release in vitro, and taken after a predetermined interval of time
Sample extracts 1ml every time, is supplemented the PBS solution of the corresponding PH of 1ml.With the PBS solution of Res（PBS solution containing 1.5%SDS）
The bent content to measure Res in corresponding release liquid of mark.
3, oil red O stain
In order to intuitively show Res-PLGA-NPS to the shadow of the fat deposition after 3T3-L1 cell, the denaturation of HepG2 cellular fat
It rings（It after OA induction for 24 hours, then is incubated for jointly for 24 hours with Res-PLGA-NPS, selects untreated cell as compareing）, using oil red
The method of O dyeing detects.Use phosphate buffered saline (PBS)（PBS）It gently washs cell three times, and is existed with 4% paraformaldehyde solution
Room temperature fixes 15min.Then, cell is washed three times with the remaining paraformaldehyde solution of removing, with freshly prepared oil red with PBS
O dyestuff（It is 3 in volume ratio：It is diluted in 2 distilled water）Working solution dyes 30min at RT, finally washes 2 with 60% isopropanol
All over to remove loose colour, PBS is infiltrated after washing 3 times with PBS.It takes pictures under the microscope observation.
Three, result：
Fig. 1 is resveratrol（Res）, PLGA and the nano-carrier that resveratrol is contained with PLGA（Res-PLGA-NPS）It is infrared
Spectrogram.The characteristic peak of PLGA is in 1757cm as seen from the figure-1Place, what it was represented is the contraction vibration of C=O key.White black false hellebore
Alcohol（Res）Show that its characteristic absorption band represents the flexible of O-H, the absorption of 964.7cm-1 at 3290cm-1 due to alcohol radical
Peak represents trans olefins key, is 1583cm-1 for C=C its absorption peak of aromatic ring that stretches, is for C-O its absorption peak that stretches
1144cm-1.In the infrared spectroscopy of Res-PLGA-NPS, it can be seen that in 1757cm-1Place and 964.7cm-1, 1583cm-1,
1144cm-1There is apparent absorption peak at place, illustrates that PLGA has successfully contained resveratrol（Res）.
Fig. 2 is the grain size distribution of Res-PLGA-NPS.As seen from the figure, the average grain diameter of Res-PLGA-NPS is
178.4nm, PDI 0.116 illustrates that the nano-carrier partial size of preparation is small, and dispersion degree and stability are all fine.
Fig. 3 is the Zeta potential distribution map of Res-PLGA-NPS.As seen from the figure, the Zeta potential of Res-PLGA-NPS be-
20.3mV is shown as negative electrical charge, and the absolute value numerical value of Zeta potential is bigger, illustrates that the system is more stable, the group of being less susceptible to
It is poly-.So -20.3mV can illustrate that the nanoparticle solution system is more stable.
Fig. 4 is the scanning electron microscope (SEM) photograph of Res-PLGA-NPS.It can clearly find out that the nano-carrier is spherical in shape by figure, and
And average grain diameter is in more than 100 rans.
Fig. 5 is the In-vitro release curves of Res in Res-PLGA-NPS.Show that resveratrol exists initially interior for 24 hours in figure
Phenomenon of burst release, release rate have reached 45% or so, that is because some drug is in carrier surface or in the surface layer shell of carrier
Interior, this part is easy release, leads to initial burst phenomenon.Drug slow release below is discharged into 65% or so when to 216h,
Play the effect of sustained release.
Fig. 6 is oil red O stain figure of the various concentration Res-PLGA-NPS to the HepG2 cell that induction is fatty liver cell.
First HepG2 cell oleic acid induced lipolysis is denaturalized, various concentration Res-PLGA-NPS is then added and is incubated for jointly, then carries out oil
Red O dyeing.If Fig. 6 can be seen that, Res-PLGA-NPS to fat inhibiting effect at concentration dependent, and have conspicuousness.
Fig. 7 is oil red O stain figure of the Res-PLGA-NPS to the 3T3-L1 fat cell of induced maturation.First by 3T3-L1
It is mature fat cell that PECTORAL LIMB SKELETON is induced with " cocktail " method, adds Res-PLGA-NPS and is incubated for jointly, most laggard
Row oil red O stain.As can be seen from Figure, after Res-PLGA-NPS being added, triglycerides in fat cell can obviously be inhibited
Accumulation, illustrate that Res-PLGA-NPS has the function of fat reducing.
Embodiment 2
Carry the preparation of the nanoparticle of resveratrol：
30mgPLGA is dissolved in 3ml methylene chloride and acetone（Volume ratio is methylene chloride：Acetone=3：2）, it is molten to form uniform PLGA
Liquid（10mg/ml）.The resveratrol of 9mg is added into PLGA solution（Resveratrol is dissolved in ethyl alcohol）, and it is ultrasonic at 200w
2min generates s/o primary emulsion, and then primary emulsion is slowly injected into the BSA solution of 10 ml 1%, and surpasses at 200w
Sound 4min forms final s/o/w lotion.In order to disperse final s/o/w lotion, 10ml deionized water, magnetic agitation 4h is added
To remove remaining organic solvent.Nanoparticle is collected, 30min is centrifuged at 14000rmp and removes supernatant, to obtain NPS.So
Afterwards plus deionization is washed three times, is centrifuged 20min under 10000rpm.It is finally freeze-dried, puts 4 DEG C with spare.
Embodiment 3
Carry the preparation of the nanoparticle of resveratrol：
50mgPLGA is dissolved in 5ml methylene chloride and acetone（Volume ratio is methylene chloride：Acetone=3：2）, it is molten to form uniform PLGA
Liquid（10mg/ml）.The resveratrol of 10mg is added into PLGA solution（Resveratrol is dissolved in ethyl alcohol）, and it is ultrasonic at 250w
2min generates s/o primary emulsion, and then primary emulsion is slowly injected into the BSA solution of 15ml 1%, and ultrasonic at 250w
4min forms final s/o/w lotion.In order to disperse final s/o/w lotion, be added 15ml deionized water, magnetic agitation 4h with
Remove remaining organic solvent.Nanoparticle is collected, 30min is centrifuged at 14000rmp and removes supernatant, to obtain NPS.Then
Add deionization to wash three times, is centrifuged 20min under 10000rpm.It is finally freeze-dried, puts 4 DEG C with spare.
Claims (8)
1. a kind of preparation method for the nano-carrier for carrying resveratrol, which is characterized in that include the following steps：
（1）By drug and the organic macromolecule mixed with polymers for being dissolved in organic solvent, ultrasound is to obtain the i.e. oily phase of mixed solution；
The drug is resveratrol；
（2）By the mixed solution with containing the aqueous solution of emulsifier, i.e. water phase carries out emulsification ultrasonic treatment, to obtain water packet
Fat liquor；
（3）The oil-in-water emulsion is successively stirred, is centrifuged and carrying out washing treatment, the nano-carrier for carrying resveratrol is obtained.
2. carrying the preparation method of the nano-carrier of resveratrol according to claim 1, which is characterized in that described is organic big
Molecularly Imprinted Polymer is selected from one of PLGA, PEG, PLGA-PEG.
3. carrying the preparation method of the nano-carrier of resveratrol according to claim 1, which is characterized in that the organic solvent
Selected from one or more of acetone, methylene chloride, ethyl acetate.
4. carrying the preparation method of the nano-carrier of resveratrol according to claim 1, which is characterized in that step（1）And step
Suddenly（2）In, for the power of the ultrasound in 100 ~ 500w, ultrasonic time is 1 ~ 10min.
5. carrying the preparation method of the nano-carrier of resveratrol according to claim 1, which is characterized in that the emulsifier choosing
From one of BSA, PVA, CTAB, Tween 80.
6. carrying the preparation method of the nano-carrier of resveratrol according to claim 1, which is characterized in that step（3）In, institute
State mixing time be 3 ~ for 24 hours, centrifugal speed be 8000 ~ 14000rpm, washing times be 2 ~ 5 times.
7. the nano-carrier for the load resveratrol that preparation method described in claim 1 is prepared is applied to fat reducing protect liver, special
Point is that the nano-carrier for carrying resveratrol has the new application of fat reducing, protect liver.
8. to go the application of 7 nano-carriers for carrying resveratrol according to right, which is characterized in that the load resveratrol
Nano-carrier is applied in weight-reducing and liver-protecting product, plays the role of the fatty tired, product of reduction and promotes lipolysis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810741557.9A CN108888608A (en) | 2018-07-09 | 2018-07-09 | A kind of application of the preparation method and its fat reducing protect liver of the nano-carrier carrying resveratrol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810741557.9A CN108888608A (en) | 2018-07-09 | 2018-07-09 | A kind of application of the preparation method and its fat reducing protect liver of the nano-carrier carrying resveratrol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108888608A true CN108888608A (en) | 2018-11-27 |
Family
ID=64348421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810741557.9A Pending CN108888608A (en) | 2018-07-09 | 2018-07-09 | A kind of application of the preparation method and its fat reducing protect liver of the nano-carrier carrying resveratrol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108888608A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114042159A (en) * | 2021-11-01 | 2022-02-15 | 华中农业大学 | Application of Sirt1 in fatty liver injury repair |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060173060A1 (en) * | 2004-04-30 | 2006-08-03 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| WO2009129627A1 (en) * | 2008-04-25 | 2009-10-29 | Pharmascience Inc. | Novel resveratrol compositions |
| CN102641246A (en) * | 2012-03-19 | 2012-08-22 | 南京维赛医药科技有限公司 | Anti-tumor double-drug nano drug carrying microsphere and preparation method thereof |
| CN103623430A (en) * | 2013-11-28 | 2014-03-12 | 郑州大学 | Preparation method and application of targeted co-supported drug delivery system nano-particles based on polylactic-co-glycolic acid |
| CN106963743A (en) * | 2016-10-31 | 2017-07-21 | 澳门科技大学 | PLGA nano-complexes and preparation method thereof |
-
2018
- 2018-07-09 CN CN201810741557.9A patent/CN108888608A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060173060A1 (en) * | 2004-04-30 | 2006-08-03 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| WO2009129627A1 (en) * | 2008-04-25 | 2009-10-29 | Pharmascience Inc. | Novel resveratrol compositions |
| CN102641246A (en) * | 2012-03-19 | 2012-08-22 | 南京维赛医药科技有限公司 | Anti-tumor double-drug nano drug carrying microsphere and preparation method thereof |
| CN103623430A (en) * | 2013-11-28 | 2014-03-12 | 郑州大学 | Preparation method and application of targeted co-supported drug delivery system nano-particles based on polylactic-co-glycolic acid |
| CN106963743A (en) * | 2016-10-31 | 2017-07-21 | 澳门科技大学 | PLGA nano-complexes and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| JING LI ET AL: "Polyethyleneglycol-Modified Poly(d,l-lactide-co-glycolide) Loaded Resveratrol Nanoparticles Characterization and Their Anti-cancer Activities", 《JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY》 * |
| VANNA SANNA ET AL: "Effect of chitosan concentration on PLGA microcapsules for controlled release and stability of resveratrol", 《INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES》 * |
| 梅兴国主编: "《微载体药物递送系统》", 30 November 2009, 华中科技大学出版社 * |
| 陈诗慧等: "白藜芦醇对非酒精性脂肪性肝病患者血脂及血液流变学的影响", 《广州中医药大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114042159A (en) * | 2021-11-01 | 2022-02-15 | 华中农业大学 | Application of Sirt1 in fatty liver injury repair |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080020580A (en) | Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby | |
| CN116425833B (en) | Atypical hydrophobic amino acid-based self-assembled short peptide and application thereof | |
| CN102125547A (en) | Pharmaceutical composition containing gambogic acid medicament and preparation method thereof | |
| CN111557910A (en) | Liver-targeted NMN liposome nanoparticles and preparation method and application thereof | |
| Yi et al. | Synthesis, characterization, and formulation of poly-puerarin as a biodegradable and biosafe drug delivery platform for anti-cancer therapy | |
| Guan et al. | Water-dispersible astaxanthin-rich nanopowder: preparation, oral safety and antioxidant activity in vivo | |
| El Fawal et al. | Diethyldithiocarbamate/silk fibroin/polyethylene oxide nanofibrous for cancer therapy: Fabrication, characterization and in vitro evaluation | |
| CN110123754B (en) | Xanthatin nano micelle targeting dendritic cells, and preparation method and application thereof | |
| CN111632032A (en) | Natural small molecule co-assembled nano-drug delivery system and preparation method and application thereof | |
| CN114948908A (en) | Preparation method of high-load oral paclitaxel capsule for colon sustained release | |
| CN108888608A (en) | A kind of application of the preparation method and its fat reducing protect liver of the nano-carrier carrying resveratrol | |
| CN113201135B (en) | Preparation method and application of active oxygen responsive material PAM-SH | |
| CN108379241B (en) | Cholesterine hydrophobically modified Propiram-donepezil-polyoxyethylene sorbitan monoleate nanoparticle and preparation and application | |
| CN114010799A (en) | Photo-thermal synergistic chemotherapy targeted degradable nano-drug carrier and preparation method thereof | |
| CN113730597A (en) | Micro-nano carrier based on starch-curcumin conjugate and application thereof | |
| CN108888609A (en) | A kind of controlled release nanometer carrier and preparation method thereof for oral load fat reducing drug resveratrol | |
| CN109432021A (en) | A kind of the astaxanthin nanometer formulation and its preparation method of electrostatic spraying processes preparation | |
| CN109172517A (en) | A kind of preparation method of the microemulsion hydrogel as apiolin carrier with pH response | |
| CN110251487B (en) | Preparation method and application of alcohol soluble protein nanoparticles for improving drug-loading rate and oral bioavailability of docetaxel | |
| CN103989746B (en) | A kind of broussoflavone nanometer formulation and preparation method thereof | |
| CN108042492B (en) | Tartary buckwheat flavone lipid polymer nanoparticles and preparation method thereof | |
| CN103271893A (en) | Preparation method for lycopene microcapsule | |
| CN109223711A (en) | The method of film hydration method control curcuma zedoary 01 derivatives PEG-PLA micellar particle size | |
| CN113057939B (en) | Preparation method and application of chemically modified gelatin micelle coated tripterine medicine | |
| WO2018102973A1 (en) | Pegylated vitamin e periplocymarin conjugate nanoparticles and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181127 |